乳腺癌预后因素对紧急生育力保存中卵母细胞体外成熟结局的影响
研究321例18至41岁乳腺癌患者紧急生育力保存中卵母细胞体外成熟(IVM)结局,发现SBR III级、三阴性乳腺癌和HER2过表达是获卵数少或IVM结局差的独立预测因素;HER2阳性与平均成熟率<60%相关(OR 0.54;95%CI 0.30-0.97)。
要点
- SBR III级乳腺癌患者IVM获卵数和冷冻卵母细胞数显著低于SBR I或II级。
- 三阴性乳腺癌患者血清AMH水平显著低于ER/PR/HER2阳性患者。
- HER2阳性与平均成熟率<60%独立相关(OR 0.54;95%CI 0.30-0.97)。
核心结论
- 乳腺癌预后因素可能影响IVM结局。
- HER2可能参与卵巢功能和卵母细胞成熟过程。
- 需要进一步研究以更好地理解相关机制及其对IVM卵母细胞能力的可能影响。
研究设计与样本
- 研究321例18至41岁乳腺癌患者,均为卵母细胞玻璃化冷冻后IVM的候选者。
- 评估获卵数、成熟率和冷冻卵母细胞总数。
- 根据乳腺癌特征(Ki67增殖指数>20%、孕激素和/或雌激素受体表达、HER2状态和SBR分级)比较卵巢储备标志物(窦卵泡计数[AFC]和血清抗苗勒管激素[AMH]水平)和IVM结局。
- 采用逻辑回归分析确定与不良IVM结局(获卵率<50%、卵母细胞成熟率<60%和冷冻卵母细胞总数<5)独立相关的变量。
主要发现
- 总体平均年龄为32.3±4.1岁。
- 平均AFC和血清AMH水平分别为22.8±13.9个卵泡和3.8±3.1 ng/ml。
- 三阴性乳腺癌患者AMH水平显著低于ER/PR/HER2状态阳性癌症患者(3.1±2.6 ng/ml vs 4.0±3.3 ng/ml,P=0.02)。
- 平均获卵数为10.2±9.1。
- 平均成熟率为58.0±26.1%后,每周期冷冻5.8±5.3个成熟卵母细胞。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本研究为回顾性研究。
- 与许多肿瘤患者生育力保存研究一样,缺乏IVM卵母细胞再利用后的数据,无法对这些冷冻配子的结局得出可靠结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Do breast cancer (BC) characteristics influence IVM of oocytes outcomes in patients undergoing fertility preservation (FP)? SUMMARY ANSWER: Scarff-Bloom-Richardson (SBR) III grade, triple-negative BC and HER2 overexpression are independent predictors of fewer oocytes or poor IVM outcomes in young women seeking FP. WHAT IS KNOWN ALREADY: SBR grade, triple-negative status and overexpression of HER2, as well as a high Ki67 proliferation index are all established prognostic factors for BC, influencing patients' therapeutic management. Yet there are also concerns about the potential impact of cancer status on ovarian reserve and function. Previous studies analysing the results of ovarian stimulation in BC patients have shown conflicting findings. Nevertheless, there is no data on the potential impact of BC status and prognostic factors on IVM outcome in women undergoing urgent FP. STUDY DESIGN, SIZE, DURATION: We studied 321 BC patients, 18 to 41 years of age, who were also candidates for oocyte cryopreservation following IVM. The number of oocytes recovered, maturation rate and total number of cryopreserved oocytes were assessed. PARTICIPANTS/MATERIALS, SETTING, METHODS: Ovarian reserve markers (antral follicle count [AFC] and serum anti-Müllerian hormone [AMH] levels) and IVM outcomes were compared according to BC characteristics (Ki67 proliferation index >20%, progesterone and/or oestrogen receptors expression, HER2 status and SBR grade). Logistic regression analysis was then performed to determine the variables that could be independently associated with poor IVM outcomes, such as oocyte retrieval rate <50%, oocyte maturation rate <60% and total number of frozen oocytes <5. MAIN RESULTS AND THE ROLE OF CHANCE: Overall, the mean age of the population was 32.3 ± 4.1 years. Mean AFC and serum AMH levels were 22.8 ± 13.9 follicles and 3.8 ± 3.1 ng/ml, respectively. AMH levels were significantly lower in case of triple-negative BC when compared with ER/PR/HER2 status positive cancer (3.1 ± 2.6 ng/ml vs 4.0 ± 3.3 ng/ml, P = 0.02). The mean number of recovered oocytes was 10.2 ± 9.1. After a mean maturation rate of 58.0 ± 26.1%, 5.8 ± 5.3 mature oocytes were cryopreserved per cycle. The number of retrieved and cryopreserved oocytes after IVM were significantly lower in patients presenting with an SBR III tumour when compared with an SBR I or II tumour (9.6 ± 8.7 vs 11.7 ± 9.8, P = 0.02 and 5.4 ± 5.4 vs 6.6 ± 5.8, P = 0.02, respectively). Multivariate statistical analysis showed that HER2 positive status was associated with a mean maturation rate <60% (odds ratio: 0.54; 95% CI (0.30-0.97)). Ki67 and hormonal status were not correlated with poor IVM outcomes. LIMITATIONS, REASONS FOR CAUTION: A weakness is the retrospective nature of the study. Moreover, as with many studies focusing on FP in oncology patients, the lack of data after reutilization of IVM oocytes prevents drawing reliable conclusions on the fate of these frozen gametes. WIDER IMPLICATIONS OF THE FINDINGS: BC prognostic factors might influence IVM outcomes. Moreover, HER2 is likely to be involved in the ovarian function and oocyte maturation process. Further investigations are needed to better understand the mechanisms at play and their possible impact on the competence of IVM oocytes. STUDY FUNDING/COMPETING INTEREST(S): No specific funding was used and there are no conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Raad J, Sonigo C, Benoit A, et al. Influence of breast cancer prognostic factors on oocyte in vitro maturation outcomes performed for urgent fertility preservation. Hum Reprod. 2022. PMID: 35586947. doi:10.1093/humrep/deac109
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。